Recent research suggests that the shingles vaccine may offer unexpected protection against dementia, including Alzheimer's disease. Multiple studies have found that older adults vaccinated against shingles show a lower risk of cognitive decline, with some research indicating the newer Shingrix vaccine may provide even greater protection than its predecessor.

Scientists believe this protective effect is coincidental rather than intentional. The vaccine was designed to prevent varicella-zoster virus reactivation, which causes the painful shingles rash. When the virus reactivates after lying dormant in nerve cells, it triggers a blistering rash that can last weeks and cause long-term pain. The original Zostavax vaccine reduced shingles risk by 51 percent, while the newer Shingrix vaccine achieves 90-97 percent effectiveness.

Researchers have addressed concerns about healthy-user bias by using natural experiments based on vaccine rollout timing in different countries. These studies compare people who became eligible for vaccination at specific cutoff dates to those who remained ineligible, providing cleaner data. The findings suggest vaccines may play a broader role in healthy aging beyond preventing acute illness, though more research is needed to confirm these protective effects against dementia.